Wilson Disease - Neurologic Clinics
Wilson Disease - Practical Neurology
Alexion's drug meets primary goal in Phase III Wilson disease trial
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
Functional characterization of novel or yet uncharacterized ATP7B missense variants detected in patients with clinical Wilson's disease - Stalke - 2023 - Clinical Genetics - Wiley Online Library
Alexion to acquire Wilson Therapeutics in $855m deal
Wilson disease | Nature Reviews Disease Primers
Veruska Sena posted on LinkedIn
alxninvestorslides
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology
Alexion Reports Positive Results from Phase 3 Trial of ALXN1840 in Wilson Disease - Global Genes
Alexion Acquires Swedish Treatment for Wilson's Disease
Clinical Advances in Wilson Disease: A Journey From Suspicion to Diagnosis to Management
Wilson disease | Nature Reviews Disease Primers
alxninvestorslides
THINK WILSON
Alexion Pharmaceuticals - Decades of low awareness and limited scientific research of Wilson disease, a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised, have
Alexion bids $855m for rare disease biotech Wilson Therapeutics | pharmaphorum
Alexion inks $855M takeover of Wilson Therapeutics | Fierce Biotech
Biomedicines | Free Full-Text | Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the Atp7b−/− Copper Overload Mouse Model
Wilson Therapeutics - Wikipedia
Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
Wilson's Disease Treatment Market To Rise Exponentially in Future
Alexion Reports Positive Results from Phase 3 Trial of ALXN1840 in Wilson Disease - Global Genes
